🇺🇸 Paulex Bio Announces Registration of Phase 1/2a Trial of PAL-119, an Oral Small Molecule Designed to Regenerate and Restore the Function of Insulin-Producing Beta Cells

🇺🇸

First-in-human study plans to enroll healthy volunteers and adults with Type 1 or Type 2 diabetes to evaluate PAL-119’s safety and tolerability and explore its effects on the body’s own insulin production SAN DIEGO, Nov. 2, 2026 /PRNewswire/ — Paulex Bio Inc., a biopharmaceutical company…

Source: prnewswire

Country: United States